Byetta Lawsuit Website Launched by Bernstein Liebhard LLP Provides Updated Byetta Pancreatic Cancer Information, Growing Investigation and Litigation

The Firm is currently investigating Byetta lawsuit claims on behalf of patients who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking the type 2 diabetes medication.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm would like to hear from anyone who was diagnosed with these diseases after taking the drug.

New York, NY (PRWEB) June 28, 2013

Bernstein Liebhard LLP has launched a new Byetta lawsuit website dedicated to providing information to patients who may have developed pancreatitis, pancreatic cancer or thyroid cancer as a result of the diabetes drug.

The Firm is actively investigating the dangerous pancreatic risks associated with Byetta, a type II diabetes drug involved in a class of medications known as incretin mimetics. In addition to its new website, which includes information related to side effects, as well as updates on the growing nationwide litigation involving Byetta and other incretin mimetics including Januvia, Bernstein Liebhard LLP is offering free and confidential case evaluations to anyone who may have been diagnosed with any of the following diseases after taking the diabetes medication:

  •     Pancreatic Cancer
  •     Pancreatitis
  •     Thyroid Cancer

“Recent studies and regulatory action have increased concerns about the link between Byetta and pancreatic cancer, pancreatitis and thyroid cancer. Our Firm would like to hear from anyone who was diagnosed with these diseases after taking the drug,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free lawsuit consultations to anyone who may have been harmed after taking Byetta or another incretin mimetic.

Byetta Lawsuit Claims

Since Byetta was approved by the U.S. Food and Drug Administration (FDA) in April of 2005, concerns about the type II diabetes medication’s alleged potential to cause pancreatitis, pancreatic cancer and thyroid cancer have continued to mount. In 2008, the agency issued a public warning about Byetta after receiving a high number of reports involving pancreatitis, which included two deaths.* Symptoms associated with Byetta pancreatitis include abdominal pain that radiates into the back, swelling or tenderness in the abdomen, fever, increased heart rate and/or nausea and vomiting.

According to a report from USAToday.com, a study published in Gastroenterology in February 2011 found that when compared to other treatments, there was a six-fold increase of reported cases of pancreatitis linked to patients taking Januvia or Byetta; a 2.9-fold increase in reported cases of pancreatic cancer among those taking Byetta and a 2.7-fold increase of reported pancreatic cancers among Januvia users.**

Following numerous reports, including the findings of an unpublished study that found incretin mimetics like Byetta may lead to precancerous changes in the pancreas, the FDA announced on March 14, 2013 that it would be investigating this class of medications.***

As adverse event reports of Byetta pancreatic cancer, thyroid cancer and pancreatitis have increased, more Byetta lawsuit claims have been filed in the U.S. Court records show that a motion seeking the consolidation of federally-filed claims involving Byetta and other incretin mimetics has been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML). Oral

Arguments on whether to create a single federal multi-district litigation for these cases are expected to be heard at the Panel’s Hearing Session on July 25th. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Patients allegedly harmed by Byetta, Januvia or another incretin mimetic are urged to contact a Byetta attorney at Bernstein Liebhard LLP for a free legal consultation. To learn more about the link between these diabetes drugs and pancreatitis, pancreatic cancer and thyroid cancer, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, FDA, August 18, 2008
**usatoday30.usatoday.com/news/health/medical/story/2011-09-23/Popular-diabetes-drugs-may-raise-pancreatic-cancer-risk-study-suggests/50531776/1
***fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (800) 511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/